New hope for Tough-to-Treat bile duct cancer: targeted pill enters final testing phase
NCT ID NCT05987358
Summary
This study is testing whether TQB3454 tablets can help people with advanced bile duct cancer that has a specific genetic change (IDH1 mutation) and has stopped responding to standard chemotherapy. About 165 participants are randomly assigned to receive either the experimental pill or a placebo (inactive pill) to compare survival time, cancer progression, and side effects. The main goal is to see if this targeted treatment helps people live longer while maintaining their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Lanzhou University Second Hospital
Lanzhou, Gansu, 730030, China
-
Tangshan People's Hospital
Tangshan, Hebei, 063001, China
-
Third Affiliated Hospital of Naval Medical University
Shanghai, Shanghai Municipality, 200433, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300181, China
Conditions
Explore the condition pages connected to this study.